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Abstract 
One of the most important goals of pharmaceutical science is local izing the 
pharmacological activity of the drug at the site of action. Drug delivery systems 
- are. molecular tools which without undesired interaction at other sites target a 
specific drug receptor. In this work a· novel folate-cyclodextrin conjugate was 
synthesised for potential use as a drug delivery system in cancer therapy. Folate 
was directly covalently bound to an amino derivative of p-Cyclodextrin with a 
view to decreasing the polydispersity of the carrier system. Ultimately the 
cyclodextrin cavity will be used to transport drugs to the site of action. 
This study also describes the structural characterisation of the novel folate-
cyclodextrin conjugate using a range of techniques including electronic, 
vibrational, NMR, MALDI-MS and ESI-MS spectroscopies, all of which provided 
evidence that the folate moiety was bound to the cyclodextrin through an amide 
linkage. 
HPLC analysis was employed to study the purity of the conjugate prepared and 
provided evidence of the formation of a and y structural isomers. The 
photostability of the conjugate was assessed using electronic spectroscopy and the 
formation of particles was detected by light scattering. Preliminary biological 
• 
evaluation of the tumour targeting device was carried out using HeLa cells and no 
evidences of cytotoxicity are recorded. 
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Chapter 1 Introduction 
1. 1. Discovery of Cyclodextrins 
Cyclodextrins (CDs) are a family of cyclic oligosaccharides obtained from 
starch by enzymatic degradation. They were discovered in 1891 by Villiers,l and 
isolated in 1903 by Schardinger2 In the 1930s, Freudenberg et al. postulated the 
cycli~. ~tructure of CDs from a crystalline fraction of degraded starch. 3. 4, 5, 6 Later, 
in 1953, these researchers registered the first patent involving CDs which was related 
to their use in drug formulations 7 
1. 2. Chemical Structure 
Cyclodextrins consist of a(l,4)-linked D(+)glucopyranose units. The most 
common cyclodextrins are fJ.-, [3- and y-CD having 6, 7 and 8 glucose units 
respectively, as shown in figure I, The Greek letter denotes the number of glucose 
units. & 
o O~OH ~OH HO HO HO~v"i o HO~~ OH HO~H 
HO~OH HO 0 
._ L~OH doH ~oJ:f- , 
OH HO 
1 (0.c0) 
frOH ~OH HO OH H~~H H~O OH 0 o OH 
HO H)j0 OH OH 
HO ~o OH~O'b 0 ~o OH 
HO 0 OH 
HO 
2 (~·CD) 
Figure I. Most common cyclodextrin structures.9 
The topology can be represented as a toroid with the larger and the smaller 
openings exposing secondary (OH-2 and OH-3) and primary (OH-6) hydroxyl groups 
2 
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respectively. The interior of the toroid is lined by H-3, H-5 and H-6 hydrogens and 
glycosidic oxygens. The cavity is chiral and is considerably less hydrophilic than an 
aqueous environment and thus CDs are able to host hydrophobic molecules. The 
exterior is sufficiently hydrophilic to impart to cyc\odextrins water solubility. The 
toroidal geometry of cyc\odextrins is shown in figure 2.]0 
Primary Hydroxyl Faev 
OH 
Secondary Hydroxyl FacfI! 
Figu re 2. Toroidal geometry of CDs,to 
I. 3. Physico-Chemical Properties 
The physical properties of cyc\odextrins are shown in Table 1.1. The increase in 
diameter from a to y reflects· the increase in the number of glucopyranose units. It can 
be seen that the solubility of the cyclodextrins varies in an irregular manner.]] The 
relatively low solubility of j3-CD provided an early reason for its modification. Its 
annulus is of a size particularly suitable for the inclusion of drug molecules and a more 
soluble modified form would yield drug complexes with a wide range of applications. 
3 
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Table 1. Physical Properties of a-CD, P-CD and y_CD."' II 
Property a-CD P-CD y-CD 
Num her of glucopyranose units 6 7 8 
Molecular weight (anhydrous) 972.85 1134.99 1297.14 
Solubility in H20 (g per 100 cm3) 14.5 1.85 23.2 
Annular diameter measured from 4.7 6.0 7.5 
C5 hydrogens, A 
Partial molar volumes, cm3mor l 611.4 703.8 801.2 
[a]D at 25°C + 150.5 +162.5 +177.4 
pKa at 25°C 12.33 12.20 12.08 
1..4. Inclusion Compounds 
Due to the structural features of CDs, they are able to form host-guest 
inclusion complexes with hydrophobic molecules possessing the appropriate size and 
shape as shown in figure 3. Since the inner surface of the cyclodextrin is more 
hydrophobic, hydrated cyclodextrins represent a high-energy state that can readily 
include hydrophobic guest molecules in their cavities. Inclusion compounds can be 
formed with a wide range of inorganic and organic molecules and have found many 
industrial applications. One application is in drug delivery whereby using inclusion 
complexes it is possible to control the release rate of drugs. 13 CDs have also been 
used widely as stabilizing and solubilizing systems, enzyme models, catalysts, 
stationary and mobile phase additives for chiral and isomeric separations, 14. 15. 16 in 
environmental processes for water purification, and so on.17 
4 
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+ 
"' - --' .... - - - -
Figu re 3. Formation of the inclusion complex of cyclodextrin with a small guest molecule. 18 
I. 5. Functionalised Cyclodextrins 
The functionalisation of cyclodextrins allows the molecules to have improved properties 
and applications as stated above. Cyclodextrins have numerous functional groups and 
they can undergo a wide variety of chemical reactions. 19 
The most frequently studied reaction is the electrophilic attack of the hydroxyl groups. 
The a-, 13-, and y-CD contains 18,21 and 24 OHs, respectively. The multiple number of 
hydroxyl groups enables many possible modifications. There are two primary factors 
that need to be considered in the modification of the hydroxyl groups of the CDs: 
I. the nucleophilicity of the hydroxyl groups; 
2. the ability of CDs to form complexes with the reagents used. 
The -OH groups in the C6 position are the most basic and often most nucleophilic. The 
hydroxyl groups in the C2 position are the most acidic, and those at the C3 position are 
the most inaccessible. 2o, 21 
Figure 4 gives an overview of the methods which can be used for modification of 
I d . 22 cyc 0 extnns. 
5 
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1·11<lfIllBI reac1iWy. _ base (e.g. P)'f.dine) 
6-modjfied CD 
II· roversed r~ SInlIlg base (~) 
----------- 2-modified CD t:::====:==j/ /'" Iwt a n0lMlll11j>1e>fI1g _phil. 
Y 1I1-.-!Ion Y1aCQ'nj)loi:f~ 
u~e • CQ'nj)lelring ~ 
~ IV -pr!JICCl2'j)O$lIiQn, lJlI' base 
any eledrOllIlile 
V· protect 6-positioo. _ bas. 
-
2-,3· or 6 modified CD 
or a mixture of the three 
I 6·modified CD 
3-modified CD 
or 
2 modified CD 
Figure 4. Methods for the selective modification of cyclodextrins in a specific hydroxyl group.22 
The tenn mono-substituted derivative usually refers to one substituent per 
cyclodextrin ring whereas the tenn di or tri-substituted CD refers to two or three 
substituents per glucopyranose unit. CDs with a given substituent present on a 
particular position of all the glucopyranose units are generally known as per-
substituted CDs. 
There are two common ways III which the CD hydroxyls groups can be 
functionalized: 
1, monofunctionalization - functionalizing of only one hydroxyl group. 
2. per-functionalization - functionalizing of an entire set of hydroxyl groups, 
Although di- and tri-functionalizations exist, they have not been well investigated 
and are difficult to perfonn, Monofunctionalization of the CDs have, however, been 
well studied in the functionalization of these starch derivatives. 23. 24 
Substitution can be occur by directly through alkylation, acylation and sulfonation. 
Alternatively, sulfonates, halides and related species may be prepared as 
6 
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intermediates for the subsequent introduction of other substituents through 
nucleophilic displacement. Oxidation of the hydroxyl groups of the CDs produces 
aldehydes and ketones while reactions with acid chlorides. 25 
I. 6. Monosubstitution of CycIodextrins 
Monofunctionalizations can be achieved by a reaction of the hydroxyl groups 
with an electrophile. The large number of hydroxyl groups at the three different 
positions of CDs makes modification at a single desired place. The differences in the 
chemical properties and reactivity among these sites can be exploited to yield a 
specific product26 
Modification of the C6 primary hydroxyl groups on the CD is an easy way to 
attach a chemical function to the sugar rings of the cyclodextrin. A widely used 
starting material is mono-6-deoxy-6-tosyl-f3-cyclodextrin (CDTs) as depicted in 
figure 5. A common method for preparation of CDTs involves reaction of f3-CD 
with excess p-toluenesulphonyl chloride, with recrystallisation from water. 27,28 Due 
to the importance of these sulphonates acting as intermediates for the further 
synthesis of other modified CDs, many other publications exist on their preparation. 
Several nucleophiles can displace the tosyl group on the CD to yield the 
corresponding modified CD. These include nucleophiles such as iodide, aiide, 
. thioacetate, hydroxylamine, aryl or poly-alkylamine. 29,30, 31, 32 
hel 
NilOH 
--H,o 
OTs 
°4H HO 0 o HOO G 
Figu re 5. Reaction Scheme for the 6-o-mono-6-deoxy-6-tosyl-Jl-cyclodextrin synthesis, II 
7 
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[n this work CDTs is used to synthesise an amino CD which is then used to form a 
conjugate with folic acid as a potential drug delivery system. 
Although very few 2-monosybstituted CDs derivatives are known, mono-2-tosyl p-
CD has been synthesized using several strategies. m-nitrophenyl tosylate reacts with 
CD in a DMF/aqueous buffer at pH lOin a low yield. This reaction proceeds via 
complex formation to transfer the tosyl group to the 2-position. 33 
Monosubstitution at the 3-position is complicated by the fact that the hydroxyl 
groups at this position. are most inaccessible and thus less reactive compared to the 
highly accessible ones (C-2 and C-6 hydroxyl groups). Most modifications of the C-3 
OHs proceeds via the synthesis of manno-mono-2,3-epoxy CD. 34. 35 
1. 7. Drug Delivery Systems 
One of the most important goals of pharmaceutical sCience is localizing the 
pharmacological activity of the drug at the site of action. Drug delivery involves 
diagnostic and therapeutic application. Drug delivery systems (DDS) are molecular 
tools which without undesired interactions at other sites target a specific drug receptor. 
Any aberrant toxicity would be avoided and only the desired therapeutic gain would be 
produced36 These molecular systems can also offer controlled drug release37 
Advanced drug delivery systems include a targeting moiety and supplementary active 
ingredients including the carrier and drug. 38 DDS are made from a variety of organic 
and inorganic compounds such as polymers, lipids (liposomes, nanoemulsions, and 
solid-lipid nanoparticles), self-assembling amphiphilic molecules, dendrimers and 
inorganic nanocrystals39, 40, 41 Delivery of the drug-carrier system to the target site 
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does not however mean that an adequate amount of the free drug will be available at the 
actual target due to the fact that there are many additional processes that need to take 
place, These processes include drug release, endocytosis, transport of the drug across 
the cell membrane, drug-receptor binding, lysosome uptake, nuclear targeting, drug 
release and drug elimination as shown in Figure 6. 42, 43 
Drug and liposome 
o Drug release 
o 
o 
o 
Enclosomes 
0° 
° 
Cell membrane 
Release 
~~ 
~ 
Golgi ~ Lysosome 
Elimination 
Figure 6. Example of a drug....,arrier conjugate or liposome reaching the target cell so the drug 
reaches the surface of its target cell. 29 
1. 8. Cyclodextrins as Drug Carriers 
Many drugs form inclusion complexes with cyclodextrins, and the properties 
of these complexes are usually markedly different from that of the pure drug or pure 
cyclodextrin,30 CDs improve the solubilization and stabilization of drugs and they 
can be potent drug carriers for immediate and delayed delivery, CDs and their 
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derivatives, especially amphiphilic CDs, also increase drug permeability by direct 
action on mucosal membranes and enhance drug absorption imci!or bioavailability.44 . 
An equilibrium is established between the drug-CD inclusion complex and the free 
drug which allows delivery of poorly soluble drugs. One of the mechanisms 
proposed in literature is shown in figure 7 and shows that the drug can be absorbed 
by the biological membrane directly from the inclusion complex or following 
dissociation of the complex. 45 
Figure 7. Mode of penetration enhancement by CDs in drug delivery to cell membrane." 
1. 9. Folic Acid as a Targeting Agent 
Folic acid (FA) has been developed as a cancer targeting agent and is 
recognized by tumour cells due to their folate receptors (FR).46 High expression of 
FRs has been frequently observed in many types of human cancers such as ovarian, 
endometrial, colorectal, breast, lung, renal cell carcinomas, brain metastases derived 
from epithelial cancers and neuroendocrine carcinomas. Quantitative studies by Real 
Time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) confirm elevated 
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levels of FR in choriocarcinomas, meningiomas, uterine sarcomas, osteosarcomas, 
non-Hodgkin's lymphomas and preomyelocytic leukemias. 36• 37 
Folic acid is a water soluble vitamin and is a' fundamental molecule for basic 
metabolism. It is needed for the production and maintenance of cells and is required 
for the synthesis of DNA bases which are in turn needed for DNA replication. In vivo 
folic acid (pteroy-L-glutamic acid, BlO vitamin) is reduced to 7,8-dihydrofolate 
(DHF), which is subsequently reduced to 5,6,7,8-tetrahydrofolate (THF) by 
dihydrofolate reductase. THF is converted to methy lene-THF which is then reduced 
to 5-methyl-5,6,7,8-tetrahydrofolate (5-MTHF). 38 The structures of some of these 
metabolites are given in figure 8.47 Folate deficiency which is seen as an absence of 
methylene-THF results in the inhibition of the generation of red blood cells and 
therefore anemia. 
f\,,,~ ~ root] 
5: ~::-U-C-NH-fH "NrCH1 «('lI,l, N .... 4 s-"':::. I I; I : COOH ~I s""::: H,N N N 
FoUe add (FA) 
5c1 H \~-~-Glu h ~.~ N'" I *H-I H HlN~N ~ II 
11 
5,~.7,8-Te'r.hydrofollc add (I'lIF) 5-MClhyI-5,6,7,8-telt'llhydrofollc aeld (5-MTHF) 
Figure 8. Overview offolic acid and its metabolic derivatives. 38 
On the other hand in cancer therapies inihibition of cell growth is favourable. Folate 
antagonists such as aminopterine (AMP) and methotrexate (MTX) (figure 9) hamper 
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normal cellular replication and DNA synthesis. It seems that this results came from 
the inhibition' of the enzyme dihydrofolate reductase. Indeed MTX has been in use 
for more than 50 years to treat many cancers and autoimmune diseases. 47 
Figure 9. Competitive antagonists of folic acid where AMP is aminopterine and MTX is 
methotrexate. 
Therefore folate, its metabolites or its antagonists may be suitable agents for anti-
cancer therapies. In this work folate conjugated to CD is proposed as an agent to 
target tumour cells over expressing folate receptors. 
1. 10. Folic Acid Conjugates 
Folic acid receptors can be direct targets, involving antagonist drugs, or 
indirect targeting tools for delivery involving competitive drugs. This explains the 
several strategies used for folate conjugation. The conjugation of folic acid to 
therapeutic agents including alkylating agents, taxols, platinum compounds, and 
fluorouracil has been investigated. 40. 41. 48 
Folic acid has also been conjugated to polyethyleneglycol (PEG) to successfully 
deliver a wide variety of compounds including chemotherapeutic agents, 
I· I'd h . . I d d d' 42 49 50 51 52 53 o Igonuc eo!! es, p otosensltlzers, po ymers an en nmers. . . . . . 
A p-Cyclodextrin-polyethyleneglycol-folic acid conjugate (CD-PEG-FA) has been 
produced from the reaction between CD-PEG-NH2 and FA. CD-PEG-NH2 was 
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obtained through the intermediate CDTs and CD-PEG. 54 The conjugate with folic 
acid was proposed as an active tumour targeting molecule. 55. 56. 57 Another conjugate 
folate-PEG-folate-graft-polyethyleneimine (FPF-g-PEI) has also been reported and 
is described in the literature as a potential gene carrier. 58 Recently synthetic 
procedures for the production of nanoparticies of FA conjugates have been 
reported.42 
L 11. Aims and Objectives of This Work 
The aim of this work is the developmerit of new vehicles as drug delivery 
systems for cancer therapy applications.46 The synthetic strategy followed is based 
on the production of a hew cyclodextrin-folate conjugate (CDEn-FA) which involves 
reaction between an ethylenediamine modified CD and folic acid. Similar molecules 
have been reported by Caliceti at a1. using a polymer spacer (PEG) between the p-
cyclodextrin and the folate 54 However in the work presented here FA will be 
directly bound to CDEn in an attempt to eliminate the polydispersity observed in 
CDs modified with macromolecular species such as PEG. In this way we will design 
a molecular system with a controlled number of binding sites (i.e. targeting moiety, 
CD >:avity, metal coordination sites) and with properties of recognition towards 
receptor proteins. CDEn-F A can then be exploited for the intracellular delivery of 
organic and inorganic drugs or for the delivery of photo sensitizers or metal 
nanoparticles for use in Photodynamic Therapy (PDT) of tumours. 
The objectives of this work are thus to: 
• Synthesise CD En-FA. 
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• Characterise all products and reagents using a range of techniques including 
electronic, vibrational, NMR, MALDI-MS aud ESI-MS spectroscopies. 
• Investigate the photostability of CD En-FA. 
• Evaluate the biological properties of CDEn-F A. 
14 
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2. 1. Introduction 
As mentioned in Chapter 1 the syntheses of CD derivatives carried out in this 
work are based on well known reactions of ~-CD. 59, 60 
6-0-(p-Tosyl)-~-Cyclodexrin (CDTs) IS a common and extensively 
inve~tigated precursor of many cyclodextrin derivatives made from the reaction 
between p-Tosyl Chloride and ~-CD in aqueous NaOa. 11,61,62,63,60 The reaction is 
carried out at 4 DC with stirring overnight with a preliminary filtration step to remove 
the excess of umeacted chemicals64 Reverse phase chromatography can be used to 
puri.(y the material. 65 
6-(2-Aminoethyl)amino-6-deoxy-~-Cyclodextrin (CD En) can be obtained 
from the CDTs on reaction with an excess of ethylendiamine. 66, 67, 68,69, 70, 71, 72, 7J 
After reflux at 75 DC for 4 hours, the cooled product can be precipitated from acetone 
and recrystallised from a water-methanol mixture. 74 
There are no reports in the literature of methods for the preparation of a 
derivative with folate directly connected to CD. Caliceti et al. reported a method for 
the preparation of a FA-PEG-CD product. The procedure involved the synthesis of 
CD-PEG-NH2 by reaction of monotosyI-~-cyclodextrin with excess of 700 Da 
diamino-PEG. The second step involved the synthesis of CD-PEG-FA by reaction of 
CD-PEG-NH2 with folic acid. However the polyethylene glycol linkage gave 
polydispersity to the material. 54 A similar synthetic route was presented in the 
preparation of the folate-poly(ethylene glycol)-poly(L-lysine) conjugate (FOL-PEG-
PLL). It is a derivative for gene delivery applications, and its preparation involved a 
peptide bond between the carboxyl function of the folic acid and the terminal amine 
group. 50 
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The most important technique used to investigate CDs and their derivatives is 
Nuclear Magnetic Resonance (NMR) spectroscopy. Fluorescence, UV-vis 
spectroscopy, calorimetry, etc. can playa role in measuring complexation energetics 
with CDs, but usually provide only very indirect and qualititative information about 
inclusion modes and geometries. NMR spectroscopy has become the most important 
method for structural elucidation of CD, for controlling the intricate synthetic 
modifications of the CDs by modem preparative methods. 9 
The NMR experiment exploits the magnetic properties of nuclei to provide 
information on molecular structure. Only atoms with spin nuclear quantum numbers 
different than zero can show magnetic properties. Common magnetic nuclei are IH, 
IlC, 15N, 19F, 29Si and lip. When a strong magnetic field of strength Bo is turned on 
along a direction designated as the z axis, the energies of the nuclei are affected so 
that there is a group of nuclei aligned in the +z (Bo) direction and another group 
aligned in the opposite direction -z ie the energy levels split. The difference in 
energy of this representation is LlE = y h Bo / 21t, where y is the gyromagnetic ratio 
and h is Planck's constant. Therefore the frequency U = (y / 21t) B075 The signal of 
resonance for each atom depends on the local environment. So, for example, a 
hydrogen of the methyl group will give a different response than a hydrogen of the 
hydroxyl group from the same molecule. The NMR scale is set up by reference to the 
tetramethylsilane (TMS) peak at zero Hz. The chemical shift 0 (ppm) is the common 
unit used in NMR spectroscopy and is the difference between the frequency of the 
reference line divided by the reference frequency: 0 = 106 . (U-Uref)/Uref. 76 
Light can be described in terms of photons or as an electromagnetic wave. 
The Beer-Lambert law is used to describe the absorption of the light such that A = 
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EcI, where A is the absorbance, c is the concentration of sample in units of molarity, I 
is the pathlength in centimeters and E is the molar extinction coefficient (mOrl dm3 
em-I). On the absorption oflight there is a change in the system from the ground state 
to the excited state. This transition depends on the wavelength of light used and so 
_~le.ctr9.nic transitions occur in the UV -VIS range, whereas vibrational transitions 
occur in the infrared range. 
The infrared region (IR or MIR) extends from 4000 cm- I (2.5 ~m) to 400 cm-I 
(25 ~m). IR spectroscopy is a rapid, sensitive, easy to handle technique providing 
many different sampling methods for gases, liquids and solids and it is possible to 
obtain both qualitative and quantitative information. The standard format of an IR 
spectrum is transmittance [%T] versus wavenumber [cm- I], where transmittance is 
the ratio of the intensity of transmitted light to the intensity of the incident light. 
With organic compounds, characteristic vibrations of the various functional groups 
occur usually between 4000 and 1500 em-I. 77 
Electronic transitions occur in the UV -VIS range and so adsorption of 
radiation in this range excites an electron from the highest occupied molecular orbital 
(HOMO) to the lowest unoccupied molecular orbital (LUMO). The visible region 
corresponds to 400-800 nm whereas the ultraviolet region is beyond the visible in the 
200-400 nm range. The spectra are often described as bands rather than peaks and the 
wavelength at an absorption maximum is referred to as the lemax of the band. From 
this information it is' possible to estimate the molar extinction coefficient of a 
material according to the Beer-Lambert law. 78 In this work electronic spectroscopy 
is used to study the stability offolic acid and its derivative. 
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Mass spectral analyses involve the formation of gaseous ions from an analyte 
and subsequent measurement of the mass-to-charge ratio (mlz) of these ions. The 
mass spectrometer separates the ions generated upon ionization according to their 
mass-ta-charge ratio (or a related property) to give a graph of ion abundance versus 
____ ~~: _'?!'hen Electrospray Ionization Mass Spectroscopy (ESI-MS) is used, a strong 
electric field is applied to the capillary carrying the analyte solution and the spray is 
produced at atmospheric pressure. Spraying under these ,conditions produces highly 
charged droplets whose charge is determined by the polarity of the field applied to 
the capillary. Desolvation of the droplets is aided by a counter-current flow of warm 
nitrogen gas. 79 
Matrix-Assisted Laser Desorption/Ionisation-Time Of Flight Mass 
Spectrometry (MALDI-TOF MS) is a technique in which a co-precipitate of an UV-
light absorbing matrix and a molecule is irradiated by a nanosecond laser pulse. Most 
of the laser energy is absorbed by the matrix, which prevents unwanted 
fragmentation of the molecule. The ionized molecules are accelerated in an electric 
field and enter the flight tube. During the flight in this tube, different molecules are 
separated according to their mass-to-charge ratio and reach the detector at different 
times. In this way each molecule yields a distinct signal. 80 The matrix consists of 
crystalline materials such as 3,5-dimethoxy-4-hydroxycinnamic acid (sinapinic acid), 
a-cyano-4-hydroxycinnamic acid (alpha-cyano or alpha-matrix) and 2,5-
dihydroxybenzoic acid (DHB). A solution of one of these is prepared often in a 
mixture of water and an organic solvent such as acetonit~ile (ACN) or ethanol. 
Trifluoroacetic acid (TFA) may also be added. 81 
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The method is used for detection and characterization of molecules with molecular 
mass~s between 400 and 350,000 Da. It is a very sensitive method, which allows the 
detection of low quantities of sample with an accuracy of 0.1 - 0.01 %. 82,8) ES! is 
best suited for analysis of monodispersed molecules because of complications arising 
__ Jro_m __ ~e formation of multiply charged ions. Alternatively, MALDI-TOF MS is 
ide~lIy suited for characterizing polydispersed oligomers. 84 
2. 2. Instrumentation 
All reactions were monitored by thin layer chromatography (TLC) carried out 
on precoated silica-gel 60F 254 plates (E. Merck, ref. # 5554). UV detection was 
used employing a CN-6T VIlber Lourmiat UV lamp at 365 nm (6 W) and 254 nm (6 
W). 
Melting points were measured uSing the Stuart melting point SM P3 
apparatus. 
NMR spectra were recorded with an AM 300 Brucker spectrometer and a 
Varian Mercury 300 Spectrometer. lH NMR spectra were recorded at 300 MHz and 
I3C NMR spectra at 75.5 MHz. A Bruker Avance spectrometer was used for high 
resolution spectra, operating at the 700 MHz lH resonance frequency and 175 MHz 
I3C resonance frequency. Samples were dissolved in D20 or DMSO. The lH NMR 
reference peaks were the water peak, which gave a signal at 4.76 ppm, and the 
DMSO peak at 2.50 ppm. The 13C NMR reference was 1,4-Dioxane as an internal 
standard, which gave a signal at 67.19 ppm. Solutions were typically from 1 to 12 
mmo! dm-). All spectra were recorded at room temperature. 
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Infrared spectra were recorded with the Perkin-Elmer Spectrum BX FT-IR 
spectrometer. The Spectrum BX can operate in ratio, single-beam or interferogram 
modes. The optical system gives data collection over a total range of 7800 to 100 
em'!, with a maximum resolution of I cm· l Several mid infrared detectors are 
available. DTGS (Deuterated Triglycine Sulphate) or LiTaO] (lithium tantalite) 
detectors are standard and there is also the option of using MCT (Mercury Cadmium 
Telluride) or PAS (photoacoustic) detectors. The electronics system is based on the 
Motorola 68340 Integrated Processor. The instrument is connected to a PC and 
controlled using the Spectrum. Spectra were recorded of solid samples as KBr discs 
or Nujol mulls over the range of 4000-400 cm'! with background correction. 
Electronic spectra were measured using a Hewlett Packard 8453 UV -VIS 
spectrophotometer. The HP 8453 spectrophotometer is a single beam, 
microprocessor-controlled UV -Visible spectrophotometer with collimating optics. 
The detector is a diode-array (1024 photodiodes), with a spectral range from 190 to 
1100 nm, a resolution of 2 nm and a slit width of 1 um. The light source for the UV 
region is a deuterium lamp with a shine-through aperture. The lamp emits over the 
190 nm to approximately 800 nm wavelength range. The light source for the visible 
and short wave near-infrared (SWNIR) wavelength range is a low-noise tungsten 
lamp. This lamp emits light over the 370 nm to 1100 nm wavelength range. There is 
a temperature control unit also available with peltier technology. The instrument is 
connected to a PC with HP UV-Visible software. Quartz cells of 1 cm and 4 mm 
were employed for the measurements. All spectra were recorded at room temperature 
with solutions of 10.4 mol dm·]. 
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Electrospray ionisation mass spectrometry (ESI-MS) was used for the 
characterisation and purity determination of the samples. The instrument used was a 
Thermo LXQ linear trap, with potential full scan at nuzzle of 4.5 kV, flow 5 ilL/min 
and sheath gas nitrogen at 20 a.u. (arbitrary unit). The system can be used to 
_. determine molecular masses in the range 50 - 100000 Da, with an accuracy of 20 
ppm. The samples were introduced into the mass spectrometer in solution and 
ionised at atmospheric pressure. Solutions of 10-4 mol dm-] were used. 
MALDI-TOF analyses were performed on a Rerseptive (Framingham, MA) 
Voyager STR instrument equipped with delayed extraction technology. Ions were 
formed by a pulsed UV laser beam (nitrogen laser, 337 nm) and accelerated through 
24 kV. Samples were diluted in CHCiJ and mixed I: 1 v/v with the matrix solution 
obtained by dissolving 2,5-dihydroxybenzoic acid (DHB) in CH]OH/O.I % 
trifluoJoacetic acidlCH]CN (1: I: 1 by volume) at a concentration of 30 mg/mL. 
Exactly 1 ilL of this mixture was deposited onto a stainless steel 100 sample MALDI 
plate and allowed to dry at room teinperature before running the spectra in the 
positive polarity. 
2. 3_ Synthesis 
2.3. I. Synthesis of 6-o-Monotosyl-6-Deoxy-~-Cyc1odextrin (CDTs) 
~-cyclodextrin (10.01 g, 7.61 mmol) was dissolved in NaOH (100 cm], 0.4 
M) at 0°_ 4°C to which was added p-toluenesulphonyl chloride (3.00 g, 15.79 
mmol). The mixture was vigorously stirred for 4 - 5 hours at constant temperature. 
The mixture was filtered to remove the excess p-toluenesulphonyl chloride and the 
pH was reduced to.6.5 by addition of 1M HC!. A precipitate formed in the solution 
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which was then left at 4°C for 24 hours. The product was recovered by filtration, 
washed with acetone and recrystallised from water. The material was dried under 
vacuum at 60°C for at least 4 hours. 11.61,62.63.60,64 
OH OTS 
+ 
o H3C-o-~ ~-CI 
- II 
o 
• + Hel 
O.4MNaOH 
~-CD TsCl CDTs 
Figure 10. Synthesis of 6-o-Monotosyl-6-Deoxy-~-cyclodextrin (COTs). 
Yield: 1.86 g, 18% (literature value 17%).64 
m.p.: 179°C with slow decomposition (literature value 179°C with slow decomp.).64 
TLC: R/ COTs = 0.7, solvent system 7:5:5:4 ethylacetate:ethanol:water:ammonium 
sulphate; detection by dipping in 5% sulphuric acid/ethanol and heating. Analysis of 
the product showed no parent CD present at an R/ofO.l-0.5. 
Rr COTs = 0.49, solvent system 7:5:5:1 ethylacetate:ethanol:water:ammonia 30%; 
detection by dipping in 5% sulphuric acid/ethanol and heating. Analysis of the 
product showed no parent CD present at an R/of 0.38. 
IH-NMR (OM SO) t5 (ppm): 7.74 (d), 7.42 (d), 5.77 (br), 5.71 (br), 4.83 (m,), 4.49 
(br), 3.63 (br), 3.56 (br), 3.49 (br), 3.45 (br), 3.30 (br), 2.42 (s). 
BC NMR CDMSO) t5 (PpmU44.86, 132.68, 129.93, 127.62, 101.96, 81.52, 73.09, 
72.75,72.45,68.02,60.04,21.27. 
FT-IR (Nujol) u (cm·I): 2943 (s), 2902 (s), 2848 (s), 2727 (w), 2360 (w), 1653 (m), 
1463 (s), 1377 (s), 1158 (m), 1028 (m), 837 (w), 721 (w), 668 (m), 579 (w), 442 (s). 
Detail cd spectra are reported in the Appendix Section. 
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2.3.2. Synthesis of 6-Deoxy-6-[1-(2-Amino)-EthyJamino)-[3-Cyclodextrin 
(CDEn) 
COTs (9.64 g, 6.73 mmol) was dissolved in 1,2-diaminoethane (50 cm3, 0.75 
mol) and refluxed with vigorous stirring under nitrogen for 24 hours at 70°C. The 
.... mixture. was then concentrated under vacuum and gave a light yellow viscous oil. 
The oil was dissolved in a minimum volume of water-methanol 3: I (100 cm\ The 
solution was added to acetone at ·15°C obtained by mixing with liquid nitrogen. A 
white precipitate formed. The product was recovered by filtration and purified over a 
porous ceramic plate overnight. It was recrystallised from water and dried at 60°C 
for 4 hours. 66.67.68.69,70,71,72,73,74 
OTS 
• 
I3-CD eDEn' 
~NH2 
NH 
+ TsOH 
Figure 11. Preparation of6·Deoxy·6·[I·(2·Amino)·Ethylaminol·~·Cyciodextrin (CDEn). 
Yield: 6.25 g, 68% (literature value 65%). 73 
!!lj2,: 230°C with slow decomposition (value is not present in literature). 
TLC: RI CDEn = 0.65; solvent system 5:3:4:1 methanol : chloroform: water: 
ammonia; detection by dipping in 5% sulphuric acid/ethanol and heating. Analysis 
of the product showed no parent COTs present at an R,rofO.92 or En at an R/ofO.53. 
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Rr CDEn =0.19 solvent system 7:7:5:4 ethyl acetate : 2-propanol : concentrated 
ammonium hydroxide: water; detection by dipping in 5% sulphuric acid/ethanol and 
heating. 
'H NMR (D,O) 0 (ppm): 4.93 (br), 3.76 (br), 3.71 (br), 3.50 (br), 3.47 (br), 3.41 (br), 
2.(j5 .(~.r), 2.54 (br), 2.06 (br). 
BC NMR (D,O) 0 (ppm): 105.10, 104.08,86.62,84.40,75.59,74.55,74.27,73.85, 
68.34,62.76,52.30,48.02,42.03. 
, FTIR (Nujol) u (em"): 3735 (w), 2918 (s), 2852 (s), 2360 (w), 1653 (m), 1559 (w), 
1456 (8),1377 (s), 1156 (m), 1032 (m), 501 (w). 
UV-VlS, A~ (run): 210. 
ESI Mass Spectra: mlz = 1177.6 (M+H+t. 
Detailed spectra are reported in the Appendix Section. 
2.3.3. Synthesis of CD En-FA Conjugate 
CD En (0.2000 g, 0.15 mmol) was dissolved in a minimum volume of 
pyridine (15 cm\ Folic acid (0.033Q g, 0.07 mmol) and N-hydroxysuccinimide 
(0.0350 g, 0.31 mmo!) were dissolved in DMSO (10 cml ) and added to the CDEn 
solution. Dicyclohexylcarbodiimide (0.0630 g, 0.31 mmol) was added. The solution 
was stirred in the dark overnight under nitrogen at 20°C. The solution was then 
warmed to 45°C for two hours and was added to acetone (50 cml ) at -20°C. The 
·precipitate which formed was left to stand overnight. About 0.1 g of crude product 
(maximum yield 0.24 g) was recovered by filtration and washed with acetone, 
acetonitrile and diethylether. 
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H~\ 
o~o~ [0"0 OH ;;,,~ 6 DCC, NHS - !')Tid;ne I DMSO 
L __ ------,-.::l Reflux overnight 30°C under N2 
• 
CDEn CDEn-FA 
Figure 12, Preparation of CD En-FA conjugate, 
Purification of the material was carried out by column chromatography (15 x ISO 
mm) to remove any unreacted starting materials and undesired products using CM 
Sephadex C25 40-125J.l (Sigma) with gradient elution by 0+0,2M NH4HCO) (total 
volume 300 cm\ Over SO fractions of 1.5 em) were collected and followed by TLC, 
The fractions with Rr values for CDEn and folic acid were discarded. All other 
fractions were combined and a solid material recovered by rotary evaporation, This 
material was further purified by column chromatography (20 x 300 mm) on 
Sephadex 0-25 20-S0J.l to remove high molecular weight by-products, The eluent 
was deionized water (150 cm)) and fractions of 0,5 cm) were collected. A material 
was recovered for further investigation from fractions with an Rr value as given 
below. 
Yield: 0.0070 g, 3%. 
m.p,: 200°C (slow decomposition). 
TLC: RfCDEn-FA = 0,53, solvent system 5:1:3:2 propanol: ethyl acetate: water: 
ammonia; detection by dipping in 5% sulphuric acid/ethanol and heating and UV 
lamp. 
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RfCDEn-FA = 0.58 solvent system 5:3:1 propanol: water: ammonia; detection by 
dipping in 5% sulphuric acid/ethanol and heating and UV lamp . 
. IH NMR (D,O) 15 (ppm): 8.65 (s), 7.70 (d), 6.67 (d), 4.97 (br), 4.54 (m), 3.94 (s), 
3.77 (br), 3.70 (br), 3. 60 (br), 3.53 (br), 3.45 (br), 2.6~ (br), 2.23 (br), 2.08 (br), 1.87 
(br). " 
DC NMR (0,02 15 (ppm): 181.46, 178.07, 167.94, 163.04, 150.92, 146.96, 144.98, 
129.13, 115.26, 112.70, 101.98, 83.33, 81.00, 75.87, 73.31, 71.79, 68.30, 60.02, 
55.71,49.19,45.81,35.67, 33.80,28.11. 
FTIR (Nujol) u (cm'\ 3851 (w), 3735 (w), 3687 (w), 3583 (m), 2920 (s), 2853 (s), 
2726 (m), 2360 (w), 1652 (m), 1462 (s), 1377 (s), 1155 (m), 1031 (m), 721 (s),470 
(s). 
UV-VIS, Amax (nm): 194,281,354, 
ESI Mass spectra: mlz = 1600.7. 
MALDI zlm: 1602.6 (M+2Htt. 
Detailed spectra are reported in the Appendix Section. 
2. 4. Discussion 
In this section NMR shifts are assigned following the numbering system 
reported in Figure 13 and Figure 14. 
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Figure 13. Numbering of CD derivative. 
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Figure 14. Numbering ofsubstituents on the CD derivatives: a) COTs; b) CDEn; c) CDEnFA. 
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A data summary of 'H-NMR measurements is reported on the following Table 2 and an 
overview of the "C-NMR analysis is reported on 
Ta ble 3 and 4. 
29 
Chapler 2 Synthesis and Cbaraeterisation of Cyelodextrin Derivatives 
Table 2.18 NMR , petlrostopie data for II-CD and all CD Derivatives. 
Sample Hl(~) Hl H3 H4 HS H6 082 0H3 OH6 H7 H8 H9 810 811 HIl 813 HI4 HIS 816 HI9 H2O Hl2 Hl3 HlS Hl7 Hl8 
!lCD' 4.82 3.28 3.57 3.3 1 3.53 3.62 5.73 5.68 4.46 
COTs' 4.83 3.30 3.56 3.45 3.49 3.63 5.77 5.71 4.49 7.74 7.42 2.42 
COEn 4.93 3.47 3.71 3.4 1 3.50 3.76 2.06 2.65 2.54 
COEn-FA 4.97 3.53 3.70 3.45 3.60 3.77 2.08 2.65 2.23 1.87 3.94 7.70 6.67 4.54 8.65 
• Samples were dissolved in DMSO-c4 solvent. Others sample were dissolved in D,O solvent. 
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The IH-NMR spectrum obtained for P-CD in DMSO in this study showed the 
anomeric hydrogen H I(~) as a doublet at 4.82 ppm, with signals for the H2, H3, H4, 
H5 and H6 protons at 3.28, 3.61, 3.35, 3.55 and 3.62 ppm respectively. The results 
obtained for P-CD show agreement with the pattern of values published by Schneider 
el aI., who reported HI(~), H2, H3, H4, H5 and H6 at 4.82,3.29,3.64,3.34,3.59 and 
-- - - - -- . 
3.64 ppm respectively. 9 The same author reports chemical shift values for OH 
groups 5.52 (OH2), 5.48 (OH3) and 4.26 (OH6) ppm. Again there is good agreement 
with the results found in this study for OH2, OH3 and OH6 at 5.73, 5.68 and 4.46 
ppm re,spectively. Protons involved in hydrogen bonding are much more de shielded 
than free protons and therefore appear in different regions of the IH-NMR spectrum. 
OH 
6 
Secondary hydroxyl 
groups 
/ Primary hydroxyl 
~ group 
0-----
Figure 15. Structure illustrating details of the hydroxyl groups (OH-2 and OH-3) which 
participate in the formation of intramolecular bonds" 
The resonances of OH2 and OH3 were found to appear lowest field due to the 
formation of intramolecular bonds (Figure IS). 
The IH-NMR spectrum of CDTs showed III the aromatic regIOn the 
characteristic pattern of a tosyl system (two sets of doublets at 7.74 ppm and 7.42 
ppm). Both doublet groups integrated for 2 protons which is equivalent to the total 
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number of protons (four) available in the aromatic ring of the tosyl group. The same 
values are reported in the literature. 64 A singlet found at 2.42 ppm was ascribed to 
the three methyl protons of the tosyl group. The 6-hydroxyl substitution was also 
confirmed by the decrease in the integration of the peaks at 4.49-4.52 ppm from 7.74 
.... to. 7.4;2. .. These results also compare favourably with the literature.65 The IH-NMR 
spectrum of CD En does not show any tosyl group signals which suggests successful 
amination· of CDTs through nucleophilic substitution by the diaminoethane group. 
The anomeric proton has a chemical shift of 4.93 ppm and signals at 2.65 and 2.54 
ppm show the presence of methylene hydrongens (H8, H9) from the diaminoethane 
group. The signal for HI has been reported at 4.90 or 5.l0 ppm and the signal for H8 
has been reported in the range 2.70-2.90 ppm. 68,74,85 The results found in this work 
show good agreement with the literature. 
The conjugate CDEn-F A gives a spectrum as shown in Figure 16. 
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Figure 16. 'H-NMR (700 Mhz) of CD En-FA in 0,0. 
There are no reports in the literature of the synthesis of CD En-FA and therefore-there 
are no spectroscopic data available. Bonechi et al. 86 published.a paper on an NMR 
investigation of folic acid and reported chemical shift values for the aromatic protons 
H25, H19, H20 at 8.75, 7.75 and 6.74 ppm respectively. 87, 88 The 'H-NMR 
spectrum of CDEn-FA reported here does show signals in the region 8.7-6.5 ppm 
which can be assigned to these aromatic protons. However there are three signals for 
each aromatic proton. This suggested that the folic acid moiety is present in three 
different configurations and that FA is probably bonded to CDEn through both 
carboxylic functions generating y and a conjugates and there may also be some 
impurity offree FA. 
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This is further supported by looking at the signal for the anomeric hydrogen HI at 
-5 ppm which integrates for 14 protons and suggests the presence of two CD 
molecules. Integration of the peaks in the region 4 - 3 ppm assigned to the protons 
H5, H3, H4, H2 and H6 of CD also suggest two CD units . 
.. F.urthe.r .. evidence for the presence of u and y conjugates was found using ROESY 
spectroscopy and Figure 17 shows the spectra obtained. It was possible to assign 
respectively H19u, Hl9y and H20u, H20y by correlation of the signals belonging to 
the same carboxylic acid groups of both conjugates. It was also possible to show that 
. the phenyl group of the folate moiety can interact with the CD cavity by correlation 
of the peaks assigned to Hl9 and H20 of FA (6.59 and 7.51 ppm respectively) and 
the peaks assigned to the hydrogens of the CD cavity. However deep inclusion of " 
the FA group within the cavity can be excluded since no cross-peak between the 
proton of pterine ring (H25 at 8.65 ppm) and the CD cavity was detected. It may be 
possible that formation of a supramolecular adduct between CDEn-F A and unbound 
FA (free) has formed. 
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Figure 17. ROESY spectra of CD En· FA in D,O. 
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Table 3. JJC NMR spectroscopic data for Jl-CD and all CD derivatives (C I-C6). 
Sample CI C2 C3 C4 CS C6 
CD' 102.20 72.64 72.02 81.70 73.23 60.36 
COTs' 
CDEn 
CDEn-FA 
10 1.96 72.78 72.45 81.52 73.Q9 60.04 
105. 10 74.55 73.85 
10 1.98 73.3 1 71.79 
84.40 
81.00 
75.59 
75.87 
62.76 
60.02 
C I' 
104.08 
10 1.98 
C2' C3' C4' CS' C6' 
68.02 
74.27 86.62 68.34 48.02 
83.33 68.30 45.8 1 
• Samples were dissolved in DMSO-do solvent. Others sample were dissolved in D,O solvent. 
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Table 4. BC NMR spectroscopic data for II-CD and all CD derivatives (C7-C29). 
Sample C7 C8 C9 CIO Cll Cl2 C13 Cl4 CIS Cl6 Cl7 Cl8 C19 C20 C21 cn C23 C24 C2S C26 C27 C28 C29 
CDTs' 132.68 127.62 129.93 144.86 21.27 
CDEn 52.30 42.03 
CDEn-FA 49.19 35.67 178.D7 33.81 28.11 55.71 181.46 163.04 115.26 129.13 112.70 150.92 45.81 146.96 144.98 167.94 
, Samples were dissolved in OMSO-d, solvent. Others sample were dissolved in 0 ,0 solvent. 
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The spectrum of ~-cyclodextrin shows a signal for the highly deshielded anomeric 
CI at 102.20 ppm and a signal for the highly shielded C6 atom at 60.36 ppm. Signals 
for the atoms C2 and C3 as well as C5 are located in the region 72 ppm to 73 ppm. 
The signal assigned to C4 is clearly separated from other signals and is found at 
81. 70 ppm. Schneider et a19 , reported the chemical shifts of C I and C6 at 102.58 
ppm and 61.17 ppm respectively which agrees reasonably well with results reported 
here. For the atoms C2, C3, C4 and C5, Schneider et al. 9 recorded values of 72.67, 
73.89, 81.94, 72.89 ppm respectively. From this study chemical shifts at 72.75, 
72.45,81.52 and 73.09, can be similarly assigned. 
The spectrum of CDTs shows a signal for the CI atom at 101.96 ppm. Chemical 
shifts for C6 and C6' can be observed at 60.04 and 68.02 ppm respectively. For the 
atoms C2, C3, C4 and C5, literature 9 data are 7l.l, 73.1, 82.4 and 74.1 ppm 
respectively. For the atoms C2 and C3, Petter et al,64 reportedsignals·in the range 
from 73.3 to 71.4 ppm. In this study signals for the atoms C2, C3, C4 and C5 are 
74.55, 73.85, 84.40 and 75.59 ppm respectively are observed and they fit the 
literature data trend. Signals for the aromatic carbon atoms of the tosyl group can be 
seen in the range 127 to 145 ppm. The peak for the methyl substituent CII is at 
21.24 ppm. Schneider et al9 found peaks at 101.08 ppm assigned to CI, 81.00 ppm 
assigned to C4, 72.30 ppm assigned to C5 and 68.60 ppm assigned to C6' all of 
which are in agreement with the experimental data recorded here. 
The spectrum of CDEn shows chemical shifts values for the Cl atom at 105.10 and 
at 104.08 ppm for the Cl' atom. The resonance of the substituted carbon atom (C6') 
which appears at 68.02 ppm in the spectrum of CDTs was greatly shifted to 48.02 
ppm. The C6' carbon atom bonded to the tosyl group in CDTs is much more 
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de shielded than when this atom is bonded to the amine group in the CDEn. This fact 
constituted evidence that the successful replacement of the tosyl group by the amine 
group occurred. The carbon atoms C2, C3, C4 and C5 gave in the spectrum of CD En 
signals in similar position to those observed in the spectrum of CDTs. Additional 
.. signal~.were detected at 52.30 ppm and 42.03 ppm, which were assigned to C8 and 
C9 of the diaminoethane group respectively. These results are in good agreement 
with those reported by Potter et al. 89 and Fernandez et al. 85• 
The J3C-NMR spectrum of CDEn-FA has not been reported previously and 
assignments are based on data reported for folic acid. 86 It is evident that there is a 
change of chemical shift for the CI atom from 105 ppm in CDEn to 102 ppm in 
CD En-FA. For the atoms C2, C3, C4, C5 and C6 the observed values are similar to 
those of CDEn. 
Assignment of peaks in the region 120 - 180 ppm was not possible due to weak 
signals and therefore. a poor signal to noise ratio. Peaks at 49.19 and 35.67 ppm can 
be assigned to C8 and C9 respectively. The decrease in frequency can be explained 
in terms of a new charge distribution caused by formation of a peptide bond. The 
CH2- groups C12, CI3 and C23 are detected at 33.80, 28.11 and 45.81 ppm 
respectively. Chemical shifts are detected at 30.4, 26.1 and 45.9 ppm respectively. 
The aromatic carbons C18, C19, C20 and C21 gave signals at ]]'5.26, 129.13, 112.70 
and 150.92 can be assigned to atoms of folic acid. For folic acid, Bonechi et al. 86 
reported signals at 121.3, 129.0, 111.2 and 150.8 ppm, which are in good agreement 
with results obtained for CDEn'-FA.Atoms of the petirinic group C25, C26, C27 and 
C28 gave signals at 146.96, 144.98, 150.92 and 167.94 ppm respectively. Folic acid 
86 gives chemical shift values for these atoms at 148.6, 153.8, 156.2 and 161.3 ppm. 
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Table 5 shows the IR frequencies obtained for ~-CO and all derivatives with 
assignments90 
Table 5. FTIR Absorption Frequencies (em") ~-CD and its Derivatives, 
2895 2902 " " 
2727 2727 2726 -OH stretch 
2847 2848 2852 2853 -CH2- symmetric stretch 
1653 1653 1653 1653 OH- bending 
1559 N-H bending vibrations 
1463 1463 1456 1462 -CH2- scissor mode 
1377 1377 1377 1377 -CH2- symmetric bend 
1156 1158 1156 1155 Secondary and tertiary alcohol modes 
1028 1028 1032 1031 C-O stretching (cyclic alcohols) 
837 Para-Oisubstituted Benzene mode 
721 721 721 Rocking 
The spectrum of COTs shows a peak at 837 cm" which can be assigned to 
vibrations of the paradisubstituted benzene ring of the tosyl group. 
The spectrum of CDEn shows a signal at 1559 cm" assigned to the N-H bending 
vibration. 
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These results suggest successful synthesis of CDTs and CDEn. 
The spectrum of CDEn-FA does not show peaks assigned to previous intermediates. 
Electronic spectroscopy was used for spectroscopic comparison of CDEn and 
CDEn-FA. The spectrum of CDEn shows Amax at 210 run. The spectrum of the 
cOJ}jug~te shows new bands at 194,281 and 354 run. Off et at' reported absorption 
peaks for the folic acid at 280 and 350 run which agrees reasonably well with the 
bands recorded here and suggests the presence of a folic acid moiety in the 
conjugate. 
The mass spectrum (ESI-MS) of CDEn gave confirmation of the molecular 
weight from the peak' [M+H+t at 1177.6 mlz. The spectrum shows an additional 
base peak at 1219.6 mlz [M+H+t possibly caused by !be presence of a diamine ~ 
derivative such as CDEn2. 
MALDI and ESI-MS spectra of !be conjugate CDEn-FA are given in appendix O. 
These spectra confirm the formation of !be conjugated product with signals assigned 
to CDEnFA+H+ and CDEnFA+2H+ observed at mlz 1600.7 and 1602.6 respectively. 
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3. 1. Photostability of Folic Acid 
Previous studies on folic acid have shown that on heating for 10 hours at pH 
4-12 the stability decreased with decreasing pH. 92 Photodegradation of folic acid 
(FA) by ultraviolet radiation is a well-documented photochemical reaction. FA is a 
photosensitive compound that undergoes photolysis by UV. The photodegradation of 
. F A is divided into three phases leading to the formation of specific photoproducts 
such as p-aminobenzoyl-L-glutamic acid, 6-formylpterin and pterin-6-carboxylic 
acid. 93. 94 Off et al. reported that when FA is exposed to UV radiation, its absorption 
spectrum changes as shown in Figure 18.91 As can be seen there is a decrease in the 
intensity of the peak at 280 nm and an increase in intensity of the peak at 350 nm 
together with a shift in wavelength. 
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Figure 18. Absorption spectra of 10" M folic acid after 0, 20, 40 and 60 min of UV A exposure at 
pH 7. 91 
Folic acid is a polyprotic system with three major equilibrium constants (PK,I =2.38; 
pK,2=3.38; pKa3= 4,83) with a dissociation sequence NW (C28'), a-COOH (CIS) 
and y-COOH (CII), respectively. 47 The spectrum of a folate solution changes 
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significantly with irradiation time in the presence of O2 at different pH values. In 
acid media spectra are almost indistinguishable while in alkaline media spectra are 
very different. When the irradiated solutions of folate (pH 10 .;. 11) are stored in the 
dark, further changes can also be observed. 95 
3. 2. Chromatographic and Spectroscopic Study 
The CDEn-FA conjugate was evaluated by High-performance liquid 
\ 
chromatography (or high pressure. liquid chromatography) (HPLC) and UV-VIS 
analyses to gain an understanding ofthe stability and the purity of the product. 
HPLC is a column chromatography used frequently in biochemistry and 
/ 
analytical chemistry to separate, identify, and quantifY compounds. 96 The mixture to 
be separated is transferred to a column with a solvent or a solvent mixture 
(eluent/mobile phase). The column is a tube, in most cases of stainless steel, filled 
with the stationary phase. The separation occurs on the' column. Under optimal 
conditions the components to be separated pass through the stationary phase at 
different rates and leave the column after different times. The components (the 
solutes) are registered by a detector. This information is passed on to the data 
evaluation unit and the output is a chromatogram. The number of peaks is equal to 
the number of separated components in the sample, and the area is proportional to the 
amount. HPLC equipment consists at least of an eluent delivery system (pump), an 
injector, a column, a detector and a data evaluation system. 97 
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A Shimadzu HPLC system was used equipped with an SCL-IOA VP 
controller system, a Shimadzu LC-IO AD VP solvent delivery module, a SPD-MIOA 
VP UVNis photodiode array detector (PDA) and controlled by EZSTART v7.2 SPI 
Chromatography Software. A Rheodyne 8125 injector with a 20 ilL loop was used. 
The stationary phase was a Supe1co column RP C-J8 (4.6 x 25 rnm) with a mobile 
phase of phosphate buffer solution (PBS) (10 mM, pH 2.27): acetonitrile (ACN) 8:92 
v/v. Measurements were carried out with a flow rate 0.5 mLiminat room temperature 
(2S0C). HPLC analysis was carried out repetitively in order to optimis'e the 
conditions, until chromatographic reproducibility was detected. 
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As previously mentioned the detection system was a PDA unit (Figure 20) which is 
equipped with a deuterium (D2) lamp and a tungsten halogen (W) lamp. The light 
from the two lamps is mixed by a half mirror, reflected onto a concave mirror, and 
introduced into a flow cell. A shutter or a filter before the cell is automatically 
, 
inserted into the light path at each measurement of the dark signal (dark current), and 
at the automatic wavelength calibration and automatic wavelength check. The light 
which has passed through the flow cell is gathered on a slit by another mirror and 
introduced to the spectrophotometer. The light resolved into its spectral compositions 
by a holographic grating in the spectrophotometer forms a spectral image on a 
photodiode array. 512 photodiode elements are lined up on the surface of the 
photodiode array. One element is assigned every 1.2 nm of the' spectra in the range of 
190 to 800 nm. 
I CPU HL.1 _D_SP_-, 
Flowceh 
Figure 20. Schematic diagram of a Pbotodiode Array Detector. 
The UV-VIS analysis was carried out on a Hewlett Packard 8453 UV-VIS 
spectrophotometer. The details of the UV-VIS system have been previously been 
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described in Chapter' 2. CDEn-F A was studied to evaluate its stability after 
irradiation by a UV NIS light source at physiological pH. Samples of folic acid (500 
flM in PBS 10 mM, pH=7.00) and the conjugate (160 fiM in Millipore purified 
water) were irradiated with a halogen lamp (15 W) at room temperature for 5 hours 
with stirring. The irradiating beam was filtered through a I cm glass cell filled with 
water to remove the IR and UV component. During the investigation UV -VIS spectra 
were recorded to monitor any change of electronic spectra due to irradiation. 
3. 4. Results and Discussion on HPLC. 
A HPLC study of folic acid as reference was not carried out since the elution 
conditions which must be used for successful resolution of the CDEn-FA conjugate 
cannot be applied to solutions of folic acid. In the literature, many researchers 
studied folic acid by ion-pairing HPLC in very polar solvent systems. 99, 100,101, 102. 
103. 104, 105, 106, 107, 108 Folates have also been investigated by HPLC using a prevalent 
ratio of organic solvent systems or a gradient elution method at different pH values. .';. 
109, liD, 111,112,113 The results obtained in this study for CDEn-FA are shown in 
Figure 21. 
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Figure 21. Chromatogram of the CDEn-FA - mobile PBS: ACN 8:92 v/v; flow 0.5 mL/min. 
The chromatogram shows two main peaks at 2.78 (peak 1) and 3.22 (peak 2) minutes 
and a minor peak at·3.80 (peak 3) minutes. Two overlapping peaks were detected at.·,; 
4.38 (peak 4) and 4.96 (peak 5) minutes. These results are summarised in Table 6 t, 
below. 
Table 6. HPLC results for CDEn-Fa at two different flow rates with an injection volume of 10 
ilL and detection at 285 nm .. 
Flow Peak 1 Pea~2 Peak 3 Peak 4 Peak 5 
Sample 
[mLimin] tR [min) tR (min] tR (min] tR [min] tR [min] 
CDEn-FA 0,700 2,74 3,21 3,81 4,40 5,00 
CDEn-FA 0,300 4,40 5,00 5,52 5,87 6,83 
The HPLC study of CDEn-FA gave satisfactory reproducibility in terms of 
retention time. The first peak was well resolved with a tR at 2.7 minutes. A second 
well resolved peak was located at 3.2 minutes. Peak number 3 is very low in terms of 
intensity (tR= 3.8 minutes). Peak number 4 (tR=4.3 minutes) is easily detected and 
there is also a broad peak (number 5) with tR= 5.0 minutes. However the presence of 
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five peaks in the chromatogram suggests that the material is impure or it may have 
degraded. 
In an attempt to identiJY each component obtained on separation of CDEn 
UV -Vis spectra were obtained of each product exiting the HPLC column and results 
are given in Figure 22 to Figure 26. Spectra were also obtained of FA, CDEn and 
CDEn-FA and are shown in Figure 27 below and results are summarised in Table 7. 
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Figure 22. UV-VIS spectrum of first compound from HLPC showing maximum absorbance at 
275 nm. 
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Figure 23. UV-VIS spectrum of second compound from HPLC with maximum absorbance at 
198 nm, 285 nm and 365 nm. 
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Figure 24. UV-VIS spectrum of third compound from HPLC with maximum absorbance at 197 
nm, 285 nm and 365 nm. 
50 
Chapter 3 Photostability Studies 
~~ --~-4. $-iciFJ--------~: ... ----~----~- .... -- .. ----~ 
• -- nr i,i..cia!o con pH 2.27. ACN • 
. . 
, 
: ~--/ : : ; : l0. .. \!".L..1...] 
t I , • • 
I I • • • 
• • , I • 
, I , I I 
---------:----------b10 . 
20 
, . . 
o ~-~-~~-·~-~r~·~~~,,~~~:,~,'~-~-------~~----------~1r----~----;------------1cO 
· , 
-10 !. .. ,. ~ ........ , .... ' .... ~ ...... B .... ~ _,_ ~ w _ .... ~ _ ~ _ .. ' _ ........ ,. ~ ~ .... .l 
---------,---------- -10 
200 500 700 SOO 
nm 
Figure 25, UV-VIS spectrum of fourth compound from HPLC with maximum absorbance at 
275 om and 365 om. 
WlIve1enlllh: 665,3$6 run - Pmplitude; -1.074 mJ.'<.o 
30 ~ .. -....:..:..: .. 4. 2-itiFl---- .. ~-~-:------~---...:----------~ 
i'~adiato con pH 2.27 e ACN 
. 
---------~--.-------
, , 
10 10 , , , , --.------.~---------,-----.----, ---------,----------
• , . 
--- -,,~.- .. ~ .... --- .... --"; o · . r" ~ ----- .... -l-~~ ------. 
, . 
-10 !.------- ---------!---------- ·10 
200 300 500 600 700 SOO 
nm 
Figure 26. UV-VIS spectrum of fifth compound from HPLC with maximum absorbance at 198 
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Figure 27. UV-VIS spectra of Folic Acid, CDEn and CDEn-FA in PBS solntion. 
The electronic spectrum of CDEn-F A shows bands centered at 262 and 365 
run respectively and it should be very similar to the spectrum of FA because the 
CDEn can not shows a UV -Vis spectra for the absence of chromophor groups. 
The bands can be assigned to the electronic transitions in the pteridine moiety and 
the phenyl ring respectively. 114 
Table 7. Peak assignment oftbe CDEn-Fa cbromatogram. 
CDEn FA Peak 1 Peak 2 Peak 3 Peak 4 PeakS 
A,.., (nm! 210 196 olfscale 198 197 olfscale 198 
A,.., (nm! 220 215 220 
A,.., [nm! 281 275 285 285 275 285 
A,.., [nm( 352 365 365 365 365 
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From the results obtained it is very difficult to reach any conclusive 
assignments. Both CDEn and FA absorb in the 200 to 220 nm region and therefore it 
is not possible to determine which peak in the chromatogram corresponds to CDEn 
or FA or the conjugate CDEn-F A. Also, in this region could be happen some solvent 
absorption effects like peak I and 4, where there are off scale absorption phenomena. 
However peak 5 can be tentatively assigned to the conjugate. The spectrum shows 
clearly absorption features of both CDEn and FA. In particular the absorption at 198 
nm consistent with the presence of FA should be noted. Of all five spectra recorded 
only those associated with peaks 3 and 5 in the chromatogram show this absorption 
but the intensity is too weak for the spectrum of peak 3. 
Peak I in the chromatogram can possibly be assigned to some metabolite of 
FA since there is no absorption in the region above 300 nm which would be expected 
for FA itself. This peak can also not be assigned to CDEn since the cyclodextrin 
derivative does not absorb in this region. 
It is difficult to determine the origin of peaks 2, 3 and 4 in the chromatogram , .. 
since all three show absorption features of both FA and CDEn. Further analysis is 
required eg via LC-MS experiments to determine the structure of the compounds 
giving rise to these peaks in the chromatogram. 
3. 5. Results and Discussion on Photodegradation Test. 
Photodegradation tests were carried out on samples by recording UV -VIS spectra 
every hour. Figure 28 and Figure 29 show the spectra obtained over the UV -VIS 
range of 200 - 700 nm. 
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7.40) over 85 bour period. Tbe arrows sbow weak isosbestic points. 
In this study the electronic spectrum of FA shows significant changes after exposure 
to a visible light source over a 5 hour period. There are increases in intensity of the 
band centred at 281 run. There is also an increase in intensity together with a slight 
decrease in wavelength of the band centered at 352 run. This may seem at first 
glance to contradict the work of Off et al. 91 who reported a decrease in the intensity 
of the peak at 280 run. However these workers exposed FA to UV radiation and in 
our work no UV component was used. 
The spectrum of CDEn-F A does not show significant changes, in terms of 
absorbance and wavelength shifts, after irradiation experiments using the visible light 
source. As shown in Figure 29, the band at 265 run undergoes only a very small 
increase in intensity after I h of irradiation. No change was registered for the band 
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centered at 360 run. These results suggest that FA is photodegradable. However 
stability has been very much improved in the conjugate material CDEn-F A which 
may be important if the material is to be used as a drug delivery agent. 
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4. 1. Introduction 
The biological study was required in order to evaluate the performance of 
the new folate conjugate "in vitro". The design of this conjugate is based on a 
potential application in drug delivery for cancer pathology and therefore the 
biocompatibility becomes a predominant factor. 
Many researchers reported studies on cytotoxicity and uptake of drug 
delivery systems based on folate receptors. 115, 116, 117, 118, 119 To understand the 
cytotoxic effect of the CDEn-F A product in a human cancer cell line HeLa cells were 
used, HeLa cells are an immortal cell line derived from uterine cervical cancer cells 
and are used in medical research. 120 These cells are models of a human cancer cell 
with high transfection capacity and have a reliable and constant over-expression of 
the folate receptor. 121 They contain a membrane folate-binding protein (FBP) which 
is invol ved in the uptake of free folate. 122 HeLa cells have also been used to study 
inorganic nanostructured-folates. 123 
Cytology evaluation is the analysis of cells under a microscope. Cellular 
changes are used for the diagnosis of disease, to study the cellular anatomy, function 
and chemistry. 124 Trypan blue is a standard assay used in the measurement of the 
viability of cells. It is a reliable and fast test. Trypan blue, a diazo dye shown in 
Figure 30, is a vital stain used to selectively colour dead tissues or cells blue. Living 
cells or tissues with intact cell membranes are not coloured. Since cells are very 
selective in the compounds that pass through the membrane, in a viable cell Trypan 
blue is not absorbed. However, it traverses the membrane in a dead cell. Hence, dead 
cells are shown as a distinctive blue colour under a microscope. 125 
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S03H 
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HOEST 33342 is useful for monitoring cell death by apoptosis.1 26 Apoptosis and 
necrosis are two major processes by which cells die. Apoptosis is an active, 
genetically regulated disassembly of the cell from within. Disassembly creates 
changes in the phospholipid content of the cytoplasmic membrane outer layer. 
Necrosis normally results from a severe cellular disruption. 127 
4. 2. Experimental 
HeLa cells were obtained from the American-Type Culture (A TC) collection 
and propagated at 1:6 ratio using Dulbecco's modification of Eagle's minimal 
essential medium supplemented with 10% new born calf serum, 100 fl/mL of 
penicillin and 100 flg/mL of streptomycin, at 37 DC, in 5% CO2 atmosphere. The 
cells were incubated for 24 hours. 
The percentage of cell death was evaluated by microscopy in a Burker chamber, 
using the trypan blue exclusion standard assay. In a 24-well plate the cell solution 
was transferred with a density of 1.5 x 105 celis/welL 
The procedure used for was as follows: 
I. 0.5 ml of a suitable cell suspension (dilute cells in complete medium 
without serum to an approximate concentration of I x 105 to 2 x 105 cells per 
ml) were placed in a screw cap test tube. 
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2. 0.1 ml of 0.4% Trypan Blue Stain was added and mixed thoroughly. 
3. The solution was allowed to stand for 5 min at 30°C. 
4. The hemocytometer was filled for cell counting. 
5. The cells were studied under a microscope, to observe if the non-viable cells 
were stained and the viable cells excluded the stain. 128 
HeLa cells were treated for 3 hours with CDEn-F A (10.4 M) and FA (10.4 M in ratios 
of 2: I 0 and 3: \0 and afterwards they were collected and layered on poly Iysinated 
slides. After 10 min, the cells were stained with HOECHST 33342 fluorescent DNA-
binding dye at 50 mM/mL (Sigma) and analyzed (objectives 40x) by using a 
rhodamine filter (red emission) and a DAPI filter (blue emission) on a Biomed 
fluorescence microscope (Leitz, Wetzlar, Germany). 
4. 3. Results and Discussion 
The following visuals (Figure 31 to Figure 34) were obtained from the 
microscopy analysis of CDEnF A and FA as control at different ratios using Rhodamine 
filter (A), DAPI filter (B) and a combination of images is shown in C. 
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I'igure 31. HeLa cells treated with CDEn-1' A 2: lOin according to the procedure decrypted. 
Figure 32. HeLa cells treated with CD En-FA 3: lOin according to tbe procedure decrypted. 
Figure 33. HeLa cells treated witb FA 2:10 (control) in according to tbe procedure decrypted .. 
Figure 34_ HeL. cells treated witb FA 3: 10 (control) in ateording to tbe procedure decrypted. 
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During preliminary biological testing, HeLa cells were not affected when they were 
treated with eDEn-FA. The images produced when using the Rhodamine filter (A) 
for eDEn-FA and FA at all ratios studied showed a diffuse background confirming 
that both compounds were not located specifically in a cellular region. This was also 
supported by combining the images (e) and no red spots were detected. The 
conjugate seams have a better performance on the folate receptor recognition than 
free folic acid. 
When using the DAPI filter (B) for eDEn-FA and FA at all ratios studied no damage 
to the nucleic cell or no change in the morphology was observed. These results 
suggest a very low cytotoxicity for eDEn-FA. This encourages further 
experimentation on cell systems to develop CDEn-F A as a drug delivery system. 
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5. 1. Final Overview of Results 
A new material CDEn-FA was synthesized and characterized using NMR, IR 
and Mass Spectroscopy. 
From the results obtained it is clear that two structural isomers ((l- and y-) of CDEn-
FA were synthesized. Another adduct between conjugate and free FA was detected 
and was not removed after the purification process. 
HPLC studies gave further support to the spectroscopy results and also 
suggest the presence of CDEn-F A and a further adduct. 
Exposure of the new material to visible radiation showed that it is substantially more 
photostable than free FA at physiological pH values. 
A preliminary biological evaluation of the cyclodextrin-folate conjugate was carried 
out to understand its effect on HeLa cell lines. No evidence of toxicity are observed. 
At this stage there are no evidence that the material can cross the cell wall. 
The photostability tests and the biological evaluation results encourage· further 
studies on this material for applications in drug delivery systems for cancer therapy 
or diagnosis. 
5.2. Future Work 
The first goal of any future work is the separation of the two isomeric forms 
of CDEn-FA possibly by a preparative HPLC method. In this way trace products 
may be removed and the (l and y isomers of CD En-FA separated. Investigation of the 
material by NMR diffusion and Light Scattering experiments will give further 
information on its aggregation properties by competitive complexation with 
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adarnantanol. 129 Further biological tests and drug solubility properties will also be 
considered in future investigations. 130 
Protonation and metal complexation equilibria can be investigated by Capillary 
Electrophoresis and potentiometric titration studies. 131. 132 
The coordination properties of the conjugate towards different transition metal ions, 
such as ruthenium Ill, 134, 135 and platinum will be studied. 136, 137 Folic acid has 
been shown to form a coordination complex with nickel, the structure of which is 
shown below. 138 
Figure 35, Detail ofthe folic acid aromatic unit coordination to Ni'+. 138 
In this work it was shown that CDEn-FA could not cross the cell membrane cell. It 
was localized at cell wall. Therefore there is a need to study different functionalised 
CDs with more affinity for biological membranes which may help delivery into the 
cytoplasm region. 28, 139, 140, 141 Amphiphilic molecules incorporating other CD 
derivatives and porphyrin systems will be studied with a view to developing a system 
which can successfully delivery drugs into the cells. Such versatility of the CDEn-F A 
can then be exploited for intracellular delivery of photosensitisers in photodynamic 
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therapy of tumours, organic and inorganic drugs used in conventional anticancer 
therapy, metal nanoparticles. 
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Figure 40. I3C-NMR spectrum of )l-Cyclodextrin in DMSO. 
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Figure 41. I3C_NMR spectrum of 6-o-Monotosyl-6-Deoxy-p-Cyclodextrin (CDTs) in DMSO. 
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Figure 46. TOCSY spectrum of Folate Conjugate (CDEn-FA) in D,O. 
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Figure 47. IR Spectrum of p-Cyclodextrin in nujol. 
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Figure 48. IR Spectrum of 6-o-Monotosyl-6-Deoxy-p-Cyclodextrin (CDTs) in nujol. 
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